None

UTHR, Ascendis collaborate for self-injectable PAH medication

United Therapeutics (UTHR) and Ascendis Pharma have collaborated to apply Ascendis' TransCon technology platform to UTHR's treprostinil molecule.

United taps Ascendis to add long-acting value to treprostinil for PAH

United Therapeutics has signed an exclusive agreement with Ascendis Pharma to develop yet another formulation of treprostinil, the active ingredient in United's Remodulin injection, a prostacyclin va...

Ascendis, United Therapeutics deal

United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable ...

[United Therapeutics] gets rights to use [Ascendis Pharma]'s {TransCon} technology

[United Therapeutics Corp.] (hypertension, cancer, and infectious disease treatments) has licensed exclusive rights to use [Ascendis Pharma AS]’s (improves existing drugs with its linker platform) {...

United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension

SILVER SPRING, Md., Sept. 20, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis P...

Deals Of The Week: A Top Analyst Sees R&D Productivity Improving, Now Where’s The Value

Recently there’s been a more positive outlook on the industry from some sectors of Wall Street built on conviction that pharma has really improved its pipelines and, by implication, its R&D deci...

None